Genentech has multiple products on the market for serious or life-threatening medical conditions. In March 2009, Genentech became a wholly owned member of the Roche Group, and Genentech now serves as the headquarters for all Roche pharmaceutical operations in the United States. Accordingly, the list below includes products which were previously marketed as Roche products that are now being marketed by Genentech in the United States.

BioOncology Avastin® (bevacizumab)
Herceptin® (Trastuzumab)
Rituxan® (Rituximab)
Tarceva® (erlotinib)
Xeloda® (capecitabine)

Immunology and Ophthalmology ACTEMRA® (tocilizumab)
Lucentis® (ranibizumab injection)
Rituxan® (Rituximab)
Xolair® (Omalizumab) for Subcutaneous Use

Metabolism & Primary Care Activase® (Alteplase)
Boniva® (ibandronate sodium)
Cathflo® Activase® (Alteplase)
Nutropin® [somatropin (rDNA origin) for injection]
Nutropin AQ® [somatropin (rDNA origin) injection]
Nutropin AQ Pen® for use with Nutropin AQ Pen® Cartridge [somatropin (rDNA origin) injection]
TNKase® (Tenecteplase)

Virology & Specialty Care CellCept® (mycophenolate mofetil)
Fuzeon® (enfuvirtide)
Invirase® (saquinavir mesylate)
Pegasys® (peginterferon alfa-2a)
Pulmozyme® (dornase alfa)
Tamiflu® (oseltamivir phosphate)
Valcyte® (valganciclovir HCL)

Other Products Accutane® (isotretinoin)
Anaprox® (naproxen sodium)
Cytovene® (ganciclovir)
EC-Naprosyn® (naproxen)
Fansidar® (sulfadoxine + pyrimethamine)
Gantrisin® (sulfisoxazole)
Klonopin® (clonazepam)
Kytril® (granisetron HCL)
Naprosyn® (naproxen)
Raptiva® (efalizumab) (Withdrawn from U.S. market April 8, 2009)
Rocephin® (ceftriaxone)
Roferon®-A (interferon alfa-2a)
Romazicon® (flumazenil)
Valium® (diazepam)
Vesanoid® (tretinoin)
Xenical® (orlistat)
Zenapax® (daclizumab)